U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H22FN7O
Molecular Weight 407.4441
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SELTOREXANT

SMILES

[H][C@@]12CN(C[C@]1([H])CN(C2)C3=NC(C)=CC(C)=N3)C(=O)C4=C(C=CC=C4F)N5N=CC=N5

InChI

InChIKey=SQOCEMCKYDVLMM-IYBDPMFKSA-N
InChI=1S/C21H22FN7O/c1-13-8-14(2)26-21(25-13)28-11-15-9-27(10-16(15)12-28)20(30)19-17(22)4-3-5-18(19)29-23-6-7-24-29/h3-8,15-16H,9-12H2,1-2H3/t15-,16+

HIDE SMILES / InChI

Molecular Formula C21H22FN7O
Molecular Weight 407.4441
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

2-(4,6-DIMETHYLPYRIMIDIN-2-YL)-5-((2-FLUORO-6-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)CARBONYL)OCTAHYDROPYRROLO(3,4-C)PYRROLE (Seltorexant, MIN 202), a small molecule, selective orexin receptor type-2 antagonist, is being developed by Minerva Neurosciences and Janssen Research & Development for the treatment of insomnia and major depressive disorder. Seltorexant has shown high in vitro affinity (affinity pKi =8.0 and 6.1 for OX2R and OX1R respectively) for the human OX2R and approximates two logs selectivity ratio versus its affinity for the OX1R. Seltorexant demonstrated a dose-dependent normalization of sleep and a trend towards improvement of subjective depressive symptoms in antidepressant-treated MDD patients with residual insomnia. Additionally, seltorexant’s favorable PK profile as a potential sedative-hypnotic drug was confirmed in a MDD population and did not demonstrate unacceptable adverse events or unwanted next-day CNS effects. Seltorexant is in phase II clinical trials for both insomnia and MDD.

Approval Year

PubMed

PubMed

TitleDatePubMed
A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.
2018 Jun
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia.
2019 Feb

Sample Use Guides

Twenty male and female patients received a single dose of 10, 20, 40 mg seltorexant and placebo with a washout period of seven days in a double-blind four-way crossover study.
Route of Administration: Oral
Seltorexant has shown high in vitro affinity (affinity pKi =8.0 and 6.1 for OX2R and OX1R respectively) for the human OX2R and approximates two logs selectivity ratio versus its affinity for the OX1R.
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:25:17 UTC 2023
Edited
by admin
on Sat Dec 16 08:25:17 UTC 2023
Record UNII
AIS8N3O50B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SELTOREXANT
INN   WHO-DD  
INN  
Official Name English
JNJ-42847922
Code English
(5-(4,6-DIMETHYL-2-PYRIMIDINYL)HEXAHYDROPYRROLO(3,4-C)PYRROL-2(1H)-YL)(2-FLUORO-6-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE
Systematic Name English
((3AR,6AS)-5-(4,6-DIMETHYLPYRIMIDIN- 2-YL)HEXAHYDROPYRROLO(3,4-C)PYRROL-2(1H)-YL)(2-FLUORO- 6-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE OREXIN RECEPTOR ANTAGONIST
Common Name English
Seltorexant [WHO-DD]
Common Name English
METHANONE, ((3AR,6AS)-5-(4,6-DIMETHYL-2-PYRIMIDINYL)HEXAHYDROPYRROLO(3,4-C)PYRROL-2(1H)-YL)(2-FLUORO-6-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)-, REL-
Common Name English
SELTOREXANT [USAN]
Common Name English
2-(4,6-DIMETHYLPYRIMIDIN-2-YL)-5-((2-FLUORO-6-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)CARBONYL)OCTAHYDROPYRROLO(3,4-C)PYRROLE
Systematic Name English
MIN-202
Code English
METHANONE, (5-(4,6-DIMETHYL-2-PYRIMIDINYL)HEXAHYDROPYRROLO(3,4-C)PYRROL-2(1H)-YL)(2-FLUORO-6-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)-
Systematic Name English
seltorexant [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C265
Created by admin on Sat Dec 16 08:25:17 UTC 2023 , Edited by admin on Sat Dec 16 08:25:17 UTC 2023
Code System Code Type Description
DRUG BANK
DB14961
Created by admin on Sat Dec 16 08:25:17 UTC 2023 , Edited by admin on Sat Dec 16 08:25:17 UTC 2023
PRIMARY
INN
10352
Created by admin on Sat Dec 16 08:25:17 UTC 2023 , Edited by admin on Sat Dec 16 08:25:17 UTC 2023
PRIMARY
USAN
EF-97
Created by admin on Sat Dec 16 08:25:17 UTC 2023 , Edited by admin on Sat Dec 16 08:25:17 UTC 2023
PRIMARY
PUBCHEM
86278359
Created by admin on Sat Dec 16 08:25:17 UTC 2023 , Edited by admin on Sat Dec 16 08:25:17 UTC 2023
PRIMARY
NCI_THESAURUS
C152326
Created by admin on Sat Dec 16 08:25:17 UTC 2023 , Edited by admin on Sat Dec 16 08:25:17 UTC 2023
PRIMARY
CAS
1452539-75-1
Created by admin on Sat Dec 16 08:25:17 UTC 2023 , Edited by admin on Sat Dec 16 08:25:17 UTC 2023
PRIMARY
FDA UNII
AIS8N3O50B
Created by admin on Sat Dec 16 08:25:17 UTC 2023 , Edited by admin on Sat Dec 16 08:25:17 UTC 2023
PRIMARY
CAS
1293281-49-8
Created by admin on Sat Dec 16 08:25:17 UTC 2023 , Edited by admin on Sat Dec 16 08:25:17 UTC 2023
NON-SPECIFIC STEREOCHEMISTRY
WIKIPEDIA
SELTOREXANT
Created by admin on Sat Dec 16 08:25:17 UTC 2023 , Edited by admin on Sat Dec 16 08:25:17 UTC 2023
PRIMARY MIN-202 (also known as JNJ-42847922, JNJ-922) is a selective, small-molecule antagonist of the OX2 receptor that is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceutica for the treatment of insomnia and major depressive disorder (MDD). As of December 2015, it is in phase II clinical trials for both insomnia and MDD. The chemical structure of MIN-202 has yet to be disclosed.
EPA CompTox
DTXSID201336125
Created by admin on Sat Dec 16 08:25:17 UTC 2023 , Edited by admin on Sat Dec 16 08:25:17 UTC 2023
PRIMARY
SMS_ID
100000174653
Created by admin on Sat Dec 16 08:25:17 UTC 2023 , Edited by admin on Sat Dec 16 08:25:17 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY
Drug: JNJ 42847922(Primary); Indication: Major depressive disorder; Focus: Adverse reaction; Sponsor: Janssen-Cilag; Most Recent Events: 21 Jan 2015 Preliminary results published in Minerva Neurosciences media release., 14 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record., 16 Oct 2014 Planned End Date changed from 1 Sep 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov record.